Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and DabrafenibAmir Noeparast, Jacques De Grève|Oncotarget|2016Cited by 100
Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancerAmir Noeparast, Jacques De Grève|Oncotarget|2018Cited by 31